Background and aims Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within ...

People with Pi*ZZ AATD do not naturally produce wild-type alpha-1 antitrypsin (M-AAT) protein. Thus, detecting the M-AAT protein confirms that mutant Z-AAT mRNA has been successfully edited.

The recent conference, `Alpha 1-antitrypsin deficiency and other conformational diseases', held in Airlie, Virginia, USA (27–30 June, 2000) focused on some of the common pathways by which cells ...

which is being evaluated in a phase 1/2 study for the treatment of patients with Alpha-1 Antitrypsin deficiency [AATD]. Initial results from this early-stage study are expected to be released in 2025.

Penny stocks are shares of smaller or newer companies, often in their early stages of development. These companies, however, ...

Korro Bio (KRRO) announced that it has received approval from the Australian Bellberry Human Research Ethics Committee, HREC, and clearance ...